Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II placebo-controlled study of canakinumab in adults with established rheumatoid arthritis
2006-004669-32Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Canakinumab with Placebo (2 arms). Primary endpoints: Treatment response by ACR20 at week 6 and week 12 and Biomarker profile associated with response. Started Feb 2007; status: completed.
02
Drugs
canakinumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2006-004669-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004669-32.